Banner Slide

Banner Slide

Banner Slide

Banner Slide

40 years building better todays for people with cancer

At Helsinn, we’ve made it our mission to improve the everyday lives of patients. We’ve been a family-run pharmaceutical company since we were founded 40 years ago, guided by our values of integrity, respect and with a 360-degree approach to quality that runs through everything we do. Today, we’re leading the way in supportive care in cancer, and are committed to building better todays for even more patients worldwide.

Our Business

The Helsinn Group is one of the world's leading supportive cancer care companies, with a comprehensive portfolio of medicines and therapies helping to improve the lives of patients in countries around the world.

Learn more

Corporate Social Responsibility and Sustainability

Sustainability is becoming an increasingly central part of Helsinn’s culture and business strategy. Integrity, quality and respect have always been at the core of our business, but increasingly, organisations are aware that they function as part of an ecosystem to which they have a responsibility. Care for the communities in which we operate, and stewardship of our environment, are as important to our long-term future as the economic bottom line.

Learn more

Our Products

The strength of the Helsinn model is reflected in the product candidates that we have transformed into sustainable market successes.

Learn more

Our Building Blocks

News & Events

Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase ...

Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016

Read more

Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonri...

Logo HIC RGB Sito

Helsinn Integrative Care, Helsinn’s business unit focused on evidence-based, non-pharmaceutical cancer supportive care p...

Read more

HELSINN ADVANCED SYNTHESIS 2016/2017 EDUCATION SCHOLARSHIPS FOR 11 STUDENTS IN ...

Borse di Studio HAS 2016 Foto gruppo 2

On Friday November 18, 2016, 11 students received the Helsinn AdvancedSynthesis 2016/2017 Education Scholarship of 5.000...

Read more

Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from ...

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: ME...

Read more

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nau...

Swiss approval of ALOXI® for paediatric use follows EMA approval in February 2015 and FDA approval in May 2014

Read more

HELSINN GROUP INTRODUCES HELSINN INVESTMENT FUND

Helsinn Group creates new investment fund in 40th anniversary year The new fund will focus on supporting early-stage inv...

Read more